Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | SCN4A | P35499 | 4/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138407 | 0.77 | MAPT (0.52) | MAPTL3MBTL1SCN4ASCN9AMEN1 | |
| SCHEMBL3140335 | 0.75 | MAPT (0.60) | MAPTL3MBTL1SCN4ASCN9AMEN1 | |
| SCHEMBL3143468 | 0.75 | MAPT (0.46) | MAPTL3MBTL1SCN4ASCN9AMEN1 | |
| SCHEMBL3133612 | 0.75 | MAPT (0.55) | MAPTL3MBTL1SCN4ASCN9AMEN1 | |
| SCHEMBL3128326 | 0.75 | HSD11B1 (0.51) | L3MBTL1SCN4ASCN9AMEN1KMT2A | |
| Dimethylformamide SCHEMBL27566652 | 0.74 | KMO (0.50) | MAPTL3MBTL1SCN4ASCN9AMEN1 | |
| SCHEMBL3138716 | 0.73 | MAPT (0.56) | MAPTL3MBTL1SCN4ASCN9AMEN1 | |
| SCHEMBL3129059 | 0.73 | MAPT (0.52) | MAPTL3MBTL1SCN4ASCN9AMEN1 | |
| SCHEMBL3126799 | 0.71 | KMO (0.60) | MAPTL3MBTL1MEN1KMT2ANPC1 | |
| SCHEMBL27566662 | 0.71 | NPC1 (0.51) | MAPTL3MBTL1SCN4ASCN9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265866-B1 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-07-21 | — | — | EP | disclosed |
| US-6867210-B2 | Aryl substituted pyrimidines | EURO-CELTIQUE S.A. (LU) | 2005-03-15 | — | — | US | disclosed |
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2005-02-24 | — | — | US | disclosed |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. | 2004-09-30 | — | — | US | disclosed |
| EP-1265866-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | PURDUE PHARMA L.P. | 2002-04-04 | — | — | US | disclosed |
| WO-2001068612-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, CACNA1C, KYNU | MAPT 585/4885L3MBTL1 178/4885SCN4A 88/4885 |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, KYNU, CACNA1C | MAPT 326/4885L3MBTL1 170/4885SCN4A 106/4885 |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, KYNU, CACNA1C | MAPT 326/4885L3MBTL1 170/4885SCN4A 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.